Cong L. CRISPR: Groundbreaking technology for RNA-guided genome engineering. Anal Biochem. 2017;532:87-89. doi:10.1016/j.ab.2017.05.005
Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418. doi:10.1038/nature23270
Abadi S, Yan WX, Amar D, Mayrose I. A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action. PLoS Comput Biol. 2017;13(10):e1005807. doi:10.1371/journal.pcbi.1005807
Hazelbaker DZ, Beccard A, Bara AM, et al. A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease. Stem Cell Reports. 2017;9(4):1315-1327. doi:10.1016/j.stemcr.2017.09.006
Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280-284. doi:10.1038/nature24049
Komor AC, Badran AH, Liu DR. Editing the Genome Without Double-Stranded DNA Breaks. ACS Chem Biol. 2018;13(2):383-388. doi:10.1021/acschembio.7b00710
Tothova Z, Krill-Burger JM, Popova KD, et al. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell. 2017;21(4):547-555.e8. doi:10.1016/j.stem.2017.07.015
Nishimasu H, Yamano T, Gao L, Zhang F, Ishitani R, Nureki O. Structural Basis for the Altered PAM Recognition by Engineered CRISPR-Cpf1. Mol Cell. 2017;67(1):139-147.e2. doi:10.1016/j.molcel.2017.04.019
Lucas D, O’Leary HA, Ebert BL, Cowan CA, Tremblay CS. Utility of CRISPR/Cas9 systems in hematology research. Exp Hematol. 2017;54:1-3. doi:10.1016/j.exphem.2017.06.006
Huang X, Zhou G, Wu W, et al. Genome editing abrogates angiogenesis in vivo. Nat Commun. 2017;8(1):112. doi:10.1038/s41467-017-00140-3